home All News open_in_new Full Article

Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non

Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)  Business Wire


today 15 h. ago attach_file Other

attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Other


ID: 209749693
Add Watch Country

arrow_drop_down